Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Diageo plc (DEO) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Diageo plcTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Diageo plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Diageo plc trades at $94.95 (market cap $53.05B). The key difference: Diageo plc is the larger of the two by market cap, and Diageo plc pays a 3.5% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYDEO
Market Cap
$29.60B$53.05B
Sector
HealthTechnology
52-Week High
$491.22$115.33
52-Week Low
$205.48$72.47
Enterprise Value
$27.56B$72.54B
Dividend Yield
3.5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.

The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.

Diageo plc

Diageo (DEO) trades at $93.47, down 3.75% on the day, amid mixed earnings and a $1 billion cost-cutting plan announced in August 2026. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentals reveal a P/E of 30.47, net income margin of 8.84%, and recent earnings beats in Q4 2025 and Q2 2026, offset by a Q2 2025 miss. Revenue dipped to $19.6 billion in 2026, with North America weakness pressuring results.

The outlook is cautiously optimistic, driven by cost savings and strategic shifts under CEO Dave Lewis, but risks include regional sales volatility and high debt. Analyst consensus leans buy (48.65%), with price targets suggesting upside, though execution on the turnaround plan is critical for sustained growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Diageo plc

Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.

Read more on DEO